Investor relations (EN)
This is Nanologica
Nanologica AB (publ) develops, manufactures and sells silica-based purification media for preparative chromatography to pharmaceutical manufacturers globally. The main product NLAB Saga® is a silica-based purification media with high chemical and mechanical stability specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Thanks to its efficient and long-lasting purification, NLAB Saga® can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for peptide drugs for the treatment of diabetes and obesity.
The Nanologica Group
Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances.
Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines.
The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022. The Group includes Nanologica AB (publ) and Syntagon AB.
Read more:
For further information, please contact:
Johanna Westerberg
Director IR, Communications and Marketing
Due to our large presence in the Swedish market, some material in this section is only available in Swedish. If you have any questions, kindly contact us at ir@nanologica.com.
To subscribe to our press releases and financial reports, please enter your e-mail address in the box below. You will then receive an e-mail where you need to confirm your subscription.